Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1

被引：0

作者：

Catamero, Donna ^{[1
]}

Purcell, Kiah ^{[2
]}

Ray, Chloe ^{[2
]}

Giacoia, Leora ^{[2
]}

Leahey, Sheryl ^{[3
]}

Born, Patricia ^{[4
]}

Kruyswijk, Sandy ^{[5
]}

机构：

[1] Mt Sinai Hlth Syst, New York, NY USA

[2] Mt Sinai Sch Med, New York, NY USA

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Univ Hosp Wurzburg, Wurzburg, Germany

[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NSP-03

引用

页码：S314 / S315

页数：2

共 50 条

[31] Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Dekhtiarenko, Iryna
Lelios, Iva
Attig, Jan
Sleiman, Nassim
Lazzaro, Domenico
Schindler, Emilie
Eckmann, Jan
Umana, Pablo
Jacob, Wolfgang
Schneider, Meike
Carlo-Stella, Carmelo
Mazza, Rita
Manier, Salomon
Facon, Thierry
Yoon, Sung-Soo
Koh, Youngil
Harrison, Simon J.
Er, Jeremy
Pinto, Antonio
Volzone, Francesco
Perrone, Giulia
Corradini, Paolo
Cazaubiel, Titouan
Hulin, Cyrille
Touzeau, Cyrille
Moreau, Philippe
Ocio, Enrique M.
Gaisan, Carmen Maria Montes
Popat, Rakesh
Leong, Sarah
Offner, Fritz
Otero, Paula Rodriguez
Alfonso-Pierola, Ana
Hutchings, Martin
Riley, Caroline Hasselbalch
Broske, Ann-Marie E.
BLOOD, 2022, 140 : 10137 - 10139
[32] Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
Chari, Ajai
Oriol, Albert
Krishnan, Amrita
Martinez Chamorro, Maria Del Carmen
Costa, Luciano
Mateos, Maria Victoria
Minnema, Monique C.
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Smit, M. Damiette
Ramanjulu, Swarna
Otero, Paula Rodriguez
BLOOD, 2023, 142
[33] Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Krishnan, Amrita Y.
Minnema, Monique C.
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Askari, Elham
Mateos, Maria-Victoria
Costa, Luciano J.
Verona, Raluca I.
Ma, Xuewen
Girgis, Suzette
Yang, Shiyi
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Chari, Ajai
BLOOD, 2021, 138
[34] Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
Janardan, Abhishek
Lindsay, Hammons
Szabo, Aniko
Bhatlapenumarthi, Vineel
Annyapu, Evanka
Dhakal, Binod
Narra, Ravi Kishore
Al Hadidi, Samer
Radhakrishnan, Sabarinath Venniyil
Bhutani, Divaya
Thanendrarajan, Sharmilan
Siegfried, Janz
Zangari, Maurizio
Lentzsch, Suzanne
van Rhee, Frits
D'Souza, Anita
Chakraborty, Rajshekhar
Schinke, Carolina D.
Mohan, Meera
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[35] Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody
Dekhtiarenko, Iryna
Lelios, Iva
Jacob, Wolfgang
Schneider, Meike
Weisser, Martin
Carlo-Stella, Carmelo
Manier, Salomon
Harrison, Simon J.
Popat, Rakesh
Riley, Anna Caroline Hasselbalch
Broeke, Ann-Marie E.
BLOOD, 2023, 142
[36] The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Hammons, Lindsay
Szabo, Aniko
Janardan, Abhishek
Bhatlapenumarthi, Vineel
Annyapu, Evanka
Dhakal, Binod
Al Hadidi, Samer
Radhakrishnan, Sabarinath Venniyil
Narra, Ravi
Bhutani, Divaya
Thanendrarajan, Sharmilan
Janz, Siegfried
Zangari, Maurizio
Lentzsch, Suzanne
van Rhee, Frits
Crescencio, Juan Carlos Rico
D'Souza, Anita
Chakraborty, Rajshekhar
Mohan, Meera
Schinke, Carolina
HAEMATOLOGICA, 2024, 109 (03) : 906 - 914
[37] Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
Touzeau, Cyrille
Chari, Ajai
Schinke, Carolina
Minnema, Monique C.
Berdeja, Jesus
Oriol, Albert
Van de Donk, Niels W. C. J.
Otero, Paula Rodriguez
Askari, Elham
Mateos, Maria-Victoria
Costa, Luciano J.
Caers, Jo
Rasche, Leo
Krishnan, Amrita Y.
Vishwamitra, Deeksha
Ma, Xuewen
Qin, Xiang
Gries, Katharine S.
Kato, Kelly
Campagna, Michela
Masterson, Tara
Hilder, Brandi
Tolbert, Jaszianne
Renaud, Thomas
Goldberg, Jenna D.
Heuck, Chris
Moreau, Philippe
San-Miguel, Jesus
BLOOD, 2022, 140 : 4447 - 4449
[38] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
A. M. G. A. Laheij
N. W. C. J. van de Donk
Supportive Care in Cancer, 2024, 32
[39] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
Laheij, A. M. G. A.
van de Donk, N. W. C. J.
SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
[40] Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated PatientReported Outcomes from the Phase 1/2 MonumenTAL-1 Study
Schinke, Carolina
Touzeau, Cyrille
Oriol, Albert
Mateos, Maria-Victoria
Stevens, Don A.
Rasche, Leo
Qin, Xiang
Kato, Kelly
Ming, Timothy
Katz, Eva G.
Gries, Katharine S.
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Moreau, Philippe
San-Miguel, Jesus
Rodriguez Otero, Paula
Chari, Ajai
BLOOD, 2023, 142

← 1 2 3 4 5 →